Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Circulation ; 139(18): 2157-2169, 2019 04 30.
Article in English | MEDLINE | ID: mdl-30764634

ABSTRACT

BACKGROUND: Bradyarrhythmia is a common clinical manifestation. Although the majority of cases are acquired, genetic analysis of families with bradyarrhythmia has identified a growing number of causative gene mutations. Because the only ultimate treatment for symptomatic bradyarrhythmia has been invasive surgical implantation of a pacemaker, the discovery of novel therapeutic molecular targets is necessary to improve prognosis and quality of life. METHODS: We investigated a family containing 7 individuals with autosomal dominant bradyarrhythmias of sinus node dysfunction, atrial fibrillation with slow ventricular response, and atrioventricular block. To identify the causative mutation, we conducted the family-based whole exome sequencing and genome-wide linkage analysis. We characterized the mutation-related mechanisms based on the pathophysiology in vitro. After generating a transgenic animal model to confirm the human phenotypes of bradyarrhythmia, we also evaluated the efficacy of a newly identified molecular-targeted compound to upregulate heart rate in bradyarrhythmias by using the animal model. RESULTS: We identified one heterozygous mutation, KCNJ3 c.247A>C, p.N83H, as a novel cause of hereditary bradyarrhythmias in this family. KCNJ3 encodes the inwardly rectifying potassium channel Kir3.1, which combines with Kir3.4 (encoded by KCNJ5) to form the acetylcholine-activated potassium channel ( IKACh channel) with specific expression in the atrium. An additional study using a genome cohort of 2185 patients with sporadic atrial fibrillation revealed another 5 rare mutations in KCNJ3 and KCNJ5, suggesting the relevance of both genes to these arrhythmias. Cellular electrophysiological studies revealed that the KCNJ3 p.N83H mutation caused a gain of IKACh channel function by increasing the basal current, even in the absence of m2 muscarinic receptor stimulation. We generated transgenic zebrafish expressing mutant human KCNJ3 in the atrium specifically. It is interesting to note that the selective IKACh channel blocker NIP-151 repressed the increased current and improved bradyarrhythmia phenotypes in the mutant zebrafish. CONCLUSIONS: The IKACh channel is associated with the pathophysiology of bradyarrhythmia and atrial fibrillation, and the mutant IKACh channel ( KCNJ3 p.N83H) can be effectively inhibited by NIP-151, a selective IKACh channel blocker. Thus, the IKACh channel might be considered to be a suitable pharmacological target for patients who have bradyarrhythmia with a gain-of-function mutation in the IKACh channel.


Subject(s)
Atrial Fibrillation , Atrioventricular Block , Bradycardia , G Protein-Coupled Inwardly-Rectifying Potassium Channels , Genetic Diseases, Inborn , Mutation, Missense , Amino Acid Substitution , Animals , Animals, Genetically Modified , Atrial Fibrillation/genetics , Atrial Fibrillation/metabolism , Atrial Fibrillation/pathology , Atrial Fibrillation/physiopathology , Atrioventricular Block/genetics , Atrioventricular Block/metabolism , Atrioventricular Block/pathology , Atrioventricular Block/physiopathology , Benzopyrans/pharmacology , Bradycardia/genetics , Bradycardia/metabolism , Bradycardia/pathology , Bradycardia/physiopathology , Electrophysiologic Techniques, Cardiac , Female , G Protein-Coupled Inwardly-Rectifying Potassium Channels/antagonists & inhibitors , G Protein-Coupled Inwardly-Rectifying Potassium Channels/genetics , G Protein-Coupled Inwardly-Rectifying Potassium Channels/metabolism , Genetic Diseases, Inborn/genetics , Genetic Diseases, Inborn/metabolism , Genetic Diseases, Inborn/pathology , Genetic Diseases, Inborn/physiopathology , Humans , Male , Xenopus laevis , Zebrafish
2.
J Cardiovasc Pharmacol ; 63(5): 421-7, 2014 May.
Article in English | MEDLINE | ID: mdl-24805146

ABSTRACT

The present study examines the effects of NTC-801, a highly selective acetylcholine (ACh) receptor-activated potassium (KACh) channel blocker, on atrial fibrillation (AF) in a canine model with electrical remodeling. An experimental substrate for AF was created in dogs via left atrial (LA) tachypacing (400 bpm, 3-5 weeks). NTC-801, dofetilide, and flecainide were intravenously infused for 15 minutes, and the effects on AF inducibility, atrial effective refractory period (ERP), and atrial conduction velocity were examined. The effect of NTC-801 on AF termination was also evaluated. Atrial ERP was shortened and AF inducibility was increased after LA tachypacing. NTC-801 (0.3-3 µg·kg⁻¹·min⁻¹) prolonged atrial ERP irrespective of stimulation frequency and dose-dependently decreased AF inducibility. Dofetilide (5.3 µg·kg⁻¹·min⁻¹) and flecainide (0.13 mg·kg⁻¹·min⁻¹) did not significantly inhibit AF inducibility and minimally affected atrial ERP. Flecainide decreased atrial conduction velocity, whereas NTC-801 and dofetilide did not. NTC-801 (0.1 mg/kg) converted AF to normal sinus rhythm. In summary, NTC-801 exerted more effective antiarrhythmic effects than dofetilide and flecainide in a canine LA-tachypacing AF model. The antiarrhythmic activity of NTC-801 was probably due to prolonging atrial ERP independently of stimulation frequency. These results suggest that NTC-801 could prevent AF more effectively in the setting of atrial electrical remodeling.


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/drug therapy , Potassium Channel Blockers/therapeutic use , Receptors, Cholinergic/drug effects , Animals , Cardiac Pacing, Artificial , Dogs , Electrocardiography/drug effects , Flecainide/therapeutic use , Heart Atria/drug effects , Heart Conduction System/drug effects , Phenethylamines/therapeutic use , Sulfonamides/therapeutic use , Tachycardia/drug therapy , Tachycardia/physiopathology
3.
Masui ; 61(8): 885-8, 2012 Aug.
Article in Japanese | MEDLINE | ID: mdl-22991819

ABSTRACT

A 76-year-old man implanted with a CRT-P device (cardiac resynchronization therapy pacemaker) was diagnosed with renal tumor by chance. Right laparoscopic nephrectomy was performed under general and epidural anesthesia. Urologists were going to use a monopolar electrocautery during the operation. Before beginning the operation, we converted his pacing mode from DDD to DOO with a precordial magnet because electrocautery has the potential for causing device reset. His blood pressure and heart rate were stable during DOO mode. When the former CRT-P, for example InSync8040 (Medtronic) which we reported in 2009, was converted from DDD mode to DOO mode, the optimal atrioventricular (AV) delay had become invalid in DOO mode. In this case, new device Syncra (Medtronic) which had been marketed in March 2011 was implanted. DOO mode could be used keeping the optimal AV delay and right ventricular-left ventricular delay and the effect of cardiac resynchronization was valid. New CRT-P could be managed as single chamber or double chamber pacemaker. Recently in Japan, CRT becomes more common and operations in the patients implanted with CRT-P or CRT-D (CRT with defibrillation) will become more frequent. CRT will require attention for anesthetic management.


Subject(s)
Anesthesia, Epidural , Anesthesia, General , Cardiac Resynchronization Therapy Devices , Intraoperative Care , Laparoscopy , Nephrectomy , Aged , Electrocoagulation/adverse effects , Humans , Kidney Neoplasms/surgery , Laparoscopy/methods , Male , Nephrectomy/methods
4.
Circ Arrhythm Electrophysiol ; 4(1): 94-102, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21156770

ABSTRACT

BACKGROUND: The acetylcholine-activated K(+) current (I(K,ACh)) is a novel candidate for atrial-specific antiarrhythmic therapy. The present study investigates the involvement of I(K,ACh) in atrial fibrillation (AF) using NTC-801, a novel potent and selective I(K,ACh) blocker. METHODS AND RESULTS: The effects of NTC-801, substituted 4-(aralkylamino)-2,2-dimethyl-3,4-dihydro-2H-benzopyran-3-ol, on I(K,ACh) and other cardiac ionic currents (I(Na), I(CaL), I(to), I(Kur), I(Kr), I(Ks), I(Kl), I(KATP), and I(f)) and on atrial and ventricular action potentials were examined in vitro. NTC-801 potently inhibited carbachol-induced I(K,ACh) in guinea pig atrial cells and the GIRK1/4 current in Xenopus oocytes with IC(50) values of 5.7 and 0.70 nmol/L, respectively. NTC-801 selectively inhibited I(K,ACh) >1000-fold over other cardiac ionic currents. NTC-801 (10 to 100 nmol/L) reversed the action potential duration (APD(90)) shortened by carbachol or adenosine in atrial cells, whereas it did not affect APD(90) at 100 nmol/L in ventricular cells. Antiarrhythmic effects of NTC-801 were evaluated in 3 AF models in vivo. NTC-801 significantly prolonged atrial effective refractory period without affecting ventricular effective refractory period under vagal nerve stimulation. NTC-801 dose-dependently converted AF to normal sinus rhythm in both vagal nerve stimulation-induced (0.3 to 3 µg · kg(-1) · min(-1) IV) and aconitine-induced (0.01 to 0.1 mg/kg IV) models. In a rapid atrial pacing model, NTC-801 (3 µg · kg(-1) · min(-1) IV) significantly decreased AF inducibility with a prolonged atrial effective refractory period that was frequency-independent. CONCLUSIONS: A selective I(K,ACh) blockade induced by NTC-801 exerted anti-AF effects mediated by atrial-selective effective refractory period prolongation. These findings suggest that I(K,ACh) may be important in the development and maintenance of AF.


Subject(s)
Acetylcholine , Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/drug therapy , Potassium Channel Blockers/therapeutic use , Action Potentials/drug effects , Action Potentials/physiology , Animals , Anti-Arrhythmia Agents/pharmacology , Atrial Fibrillation/physiopathology , Benzopyrans/pharmacology , Cells, Cultured , Cricetinae , Cricetulus , Dogs , Dose-Response Relationship, Drug , Female , Guinea Pigs , HEK293 Cells , Heart Atria/cytology , Heart Atria/drug effects , Heart Atria/physiopathology , Humans , Models, Animal , Oocytes/drug effects , Potassium Channel Blockers/pharmacology , Potassium Channels/drug effects , Potassium Channels/physiology , Vagus Nerve/drug effects , Vagus Nerve/physiopathology , Xenopus
6.
J Palliat Med ; 13(4): 401-6, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20384500

ABSTRACT

PURPOSE: In February 2002, the palliative care team was established in Ikeda Municipal Hospital to improve palliative care. We investigated changes in the incidences of side effects related to opioids, and evaluated palliative care team activities. METHODS: Regarding inpatients for whom narcotics were prescribed in our hospital in the years of 2002 (from October 1, 2002 until September 30, 2003), 2004 (from October 1, 2004 until September 30, 2005), and 2006 (from October 1, 2006 until September 30, 2007), we surveyed the rates at which laxatives or antiemetics were prescribed, frequency of defecation/its state before and after the start of narcotic therapy, frequency of nausea/vomiting, and dietary intake. RESULTS: The proportions of patients in whom laxatives were simultaneously prescribed during opioid therapy in 2002, 2004, and 2006 were 43.5%, 78.7%, and 75.6%, respectively. The proportions of those in whom antiemetics were combined with opioids were 45.7%, 78.7%, and 78.0%, respectively. The incidences of constipation were 50.0%, 39.3%, and 37.8%, respectively. Those of nausea/vomiting were 30.4%, 21.3%, and 9.8%, respectively. Those of anorexia were 65.3%, 39.4%, and 15.4%, respectively. CONCLUSIONS: These results suggest that palliative care team activities facilitated appropriate drug prescription during opioid therapy, reducing the appearance of side effects, with likelihood of improved quality of life.


Subject(s)
Analgesics, Opioid/adverse effects , Drug-Related Side Effects and Adverse Reactions , Palliative Care , Patient Care Team , Quality of Life , Aged , Anorexia/chemically induced , Constipation/chemically induced , Female , Health Care Surveys , Humans , Incidence , Inpatients , Male , Nausea/chemically induced , Risk Assessment , Risk Reduction Behavior , Vomiting/chemically induced
7.
Circ J ; 73(10): 1820-8, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19713653

ABSTRACT

BACKGROUND: This study evaluated antiarrhythmic effects of d,l-sotalol in a canine atrial fibrillation (AF) model with left ventricular dysfunction. METHODS AND RESULTS: Thirteen beagles (Sotalol group n=7 and Control group n=6) were subjected to atrial tachypacing (ATP) (400 beats/min) with intact atrioventricular conduction for 4 weeks. Oral d,l-sotalol (2 mg/kg) was administered 1 week after starting ATP and continued throughout the experiment. One week after starting ATP, atrial effective refractory periods (AERPs) were shortened in both groups. However, d,l-sotalol treatment gradually prolonged AERP, resulting in a significant prolongation of AERP compared with the Control group at 4 weeks (Control 76 +/-4 and Sotalol 126 +/-5 ms, p<0.01). d,l-Sotalol treatment showed lower AF inducibility and shorter AF duration at 4 weeks. In the control group, expressions of L-type Ca(2+) channel alpha1c and Kv4.3 mRNA were downregulated by 46.2% and 43.0%, respectively, after 4 weeks of ATP; d,l-sotalol treatment did not affect these changes. CONCLUSIONS: d,l-Sotalol treatment prolonged AERP, even after atrial electrical remodeling had developed, and prevented AF perpetuation without affecting downregulated expression of L-type Ca(2+) channel alpha1c and Kv4.3 mRNA in an ATP-induced canine AF model.


Subject(s)
Adrenergic beta-Antagonists/pharmacology , Anti-Arrhythmia Agents/pharmacology , Atrial Fibrillation/prevention & control , Atrial Function/drug effects , Sotalol/pharmacology , Ventricular Dysfunction, Left/drug therapy , Action Potentials , Administration, Oral , Adrenergic beta-Antagonists/administration & dosage , Animals , Anti-Arrhythmia Agents/administration & dosage , Atrial Fibrillation/etiology , Atrial Fibrillation/genetics , Atrial Fibrillation/pathology , Atrial Fibrillation/physiopathology , Calcium Channels, L-Type/genetics , Cardiac Pacing, Artificial , Disease Models, Animal , Dogs , Down-Regulation , Echocardiography , Electrocardiography , Electrophysiologic Techniques, Cardiac , Fibrosis , Heart Atria/drug effects , Heart Atria/physiopathology , RNA, Messenger/metabolism , Shal Potassium Channels/genetics , Sotalol/administration & dosage , Time Factors , Ventricular Dysfunction, Left/etiology , Ventricular Dysfunction, Left/genetics , Ventricular Dysfunction, Left/pathology , Ventricular Dysfunction, Left/physiopathology , Ventricular Function, Left
8.
Yakugaku Zasshi ; 128(2): 299-304, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18239378

ABSTRACT

We established the Terminal Care Study Group, consisting of physicians, pharmacists, and nurses, in September 2001, and developed the group into the Palliative Care Team. We have surveyed the state of concomitant medications immediately before and at the beginning of opioid usage (except injections) to assess the role of the Palliative Care Team. The survey period was 3 years from October 1, 2002 to September 30, 2005. While the frequency of the prescription of non-steroidal anti-inflammatory drugs (NSAIDs), laxatives, or antiemetics before the beginning of opioid administration did not differ significantly among the 3 periods, that at the beginning of opioid administration increased significantly in 2003 compared with 2002, and increased further in 2004. Many of the drugs used were those that were recommended in our cancer pain management program. Thus, the activities of the Palliative Care Team are considered to have led to proper measures for the control of the major adverse effects of opioids such as constipation and nausea/vomiting in addition to pain control in accordance with the WHO's pain ladder, and also contributed to improvements of the patients' QOL.


Subject(s)
Analgesics, Opioid/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Antiemetics/administration & dosage , Drug Prescriptions/statistics & numerical data , Laxatives/administration & dosage , Palliative Care , Patient Care Team , Analgesics, Opioid/adverse effects , Drug Utilization/statistics & numerical data , Humans , Neoplasms/complications , Neoplasms/drug therapy , Pain, Intractable/drug therapy , Pain, Intractable/etiology , Quality of Life , Time Factors
9.
J Cardiovasc Pharmacol ; 51(2): 162-9, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18287884

ABSTRACT

We investigated the electrophysiological and antiarrhythmic effects of a novel antiarrhythmic agent, NIP-151, and compared these effects with those of an IKr-blocker dofetilide. NIP-151 potently inhibited acetylcholine-activated K current (IKACh) with an IC50, with 1.6 nM in HEK293 cells expressing the GIRK1/4 channel, but it had little effect on IKr (IC50 = 57.6 microM). NIP-151 dose-dependently terminated AF both in vagal nerve stimulation-induced AF (at 5 and 15 microg/kg per minute) and aconitine-induced AF (at 30 and 100 microg/kg) models. This compound significantly prolonged the atrial effective refractory period (ERP), but it had no significant effects on ventricular ERP. There were no significant changes on electrocardiographic variables with NIP-151 (up to 1,000 microg/kg per minute) administration. In contrast, dofetilide had little effect in either AF model, even though this compound potently prolonged atrial ERP. Dofetilide also significantly prolonged ventricular ERP and the QT interval in anesthetized dogs, which are related to proarrhythmic risk. In conclusion, a novel antiarrhythmic agent NIP-151, which potently blocked IKACh, was highly effective in the two types of canine AF models with an atrial-specific ERP-prolonging profile. Therefore, NIP-151 might be useful for the treatment of AF with lower risk of proarrhythmia, compared with IKr blockers.


Subject(s)
Anti-Arrhythmia Agents/pharmacology , Atrial Fibrillation/prevention & control , Benzopyrans/pharmacology , Aconitine , Action Potentials/drug effects , Analysis of Variance , Animals , Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/etiology , Atrial Fibrillation/physiopathology , Benzopyrans/therapeutic use , Cell Line , Dogs , Dose-Response Relationship, Drug , ERG1 Potassium Channel , Electrocardiography , Ether-A-Go-Go Potassium Channels/physiology , Female , G Protein-Coupled Inwardly-Rectifying Potassium Channels/physiology , Hemodynamics/drug effects , Humans , Inhibitory Concentration 50 , Male , Patch-Clamp Techniques , Phenethylamines/pharmacology , Potassium Channel Blockers/pharmacology , Rabbits , Refractory Period, Electrophysiological/drug effects , Sulfonamides/pharmacology , Vagus Nerve/physiopathology , Ventricular Function, Right
10.
Cardiovasc Drug Rev ; 25(4): 342-56, 2007.
Article in English | MEDLINE | ID: mdl-18078434

ABSTRACT

Atrial fibrillation (AF) is one of the most frequent cardiac arrhythmia and is associated with increased cardiovascular morbidity and mortality, and the risk of stroke. Although currently available antiarrhythmic drugs are moderately effective in restoring normal sinus rhythm in patients with AF, excessive delay of ventricular repolarization by these agents may be associated with increased risk of proarrhythmia. Therefore, selective blockers of cardiac ion channel(s) that are exclusively present in the atria are highly desirable. NIP-142 is a novel benzopyrane derivative, which blocks potassium, calcium, and sodium channels and shows atrial specific action potential duration prolongation. NIP-142 preferentially blocks the ultrarapid delayed rectifier potassium current (I Kur) and the acetylcholine-activated potassium current (I KACh). Since I Kur and I KACh have been shown to be expressed more abundantly in the atrial than in the ventricular myocardium, the atrial-specific repolarization prolonging effect of NIP-142 is considered to be due to the blockade of these potassium currents. In canine models, NIP-142 was shown to terminate the microreentry type AF induced by vagal nerve stimulation and the macroreentry type atrial flutter induced by an intercaval crush. These effects of NIP-142 have been attributed to the prolongation of atrial effective refractory period (ERP), because this compound prolonged atrial ERP without affecting intraatrial and interatrial conduction times in these models. The ERP prolongation by NIP-142 was greater in the atrium than in the ventricle. NIP-142 also terminated the focal activity type AF induced by aconitine. In addition, NIP-142 reversed the atrial ERP shortening and the loss of rate adaptation induced by short-term rapid atrial pacing in anesthetized dogs. Thus, although clinical trials are required to provide evidence for its efficacy and safety, the novel multiple ion channel blocker, NIP-142, appears to be a useful agent for the treatment of several types of AF with a low risk of proarrhythmic activity.


Subject(s)
Atrial Fibrillation/drug therapy , Benzopyrans/therapeutic use , Ion Channels/antagonists & inhibitors , Animals , Area Under Curve , Atrial Fibrillation/physiopathology , Benzopyrans/chemistry , Benzopyrans/pharmacokinetics , Delayed Rectifier Potassium Channels/antagonists & inhibitors , Delayed Rectifier Potassium Channels/physiology , Humans , Ion Channels/physiology , Membrane Potentials/drug effects , Models, Biological , Molecular Structure
11.
J Cardiovasc Electrophysiol ; 18(7): 765-72, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17472715

ABSTRACT

INTRODUCTION: This study tested whether bepridil, a multichannel blocker, would reverse electrical remodeling induced by persistent atrial tachycardia. METHODS AND RESULTS: Fourteen dogs were subjected to rapid atrial pacing at 400 bpm for 6 weeks after atrioventricular block was created to control the ventricular rate. During the study period, seven dogs were given placebo for 6 weeks (Control group), and seven were given placebo for 3 weeks, followed by 3 weeks of bepridil (10 mg/kg/day, Bepridil group). The atrial effective refractory period (ERP) and the inducibility and duration of atrial fibrillation (AF) were determined on a weekly basis. After 6 weeks, expression of L-type calcium channel alpha1C messenger ribonucleic acid (mRNA) was quantified by real-time reverse transcription-polymerase chain reaction. In the Control group, ERP was shortened and the inducibility and duration of AF increased through the 6-week period. In the Bepridil group, the same changes occurred during the first 3 weeks, but were gradually reversed with bepridil. After 6 weeks, ERP was longer, AF inducibility was lower, and AF duration was shorter in Bepridil group than in the Control group. Expression of alpha1C mRNA was decreased by 64% in the Control group (P < 0.05 vs sham), but in the Bepridil group, it was not different compared with the sham dogs. As a whole group of dogs, ERP was positively correlated with alpha1C mRNA expression. CONCLUSION: Bepridil reverses the electrophysiological consequences of atrial remodeling to some extent and L-type calcium channel downregulation in a canine model of atrial tachycardia.


Subject(s)
Bepridil/pharmacology , Calcium Channel Blockers/pharmacology , Calcium Channels, L-Type/biosynthesis , Down-Regulation/drug effects , Tachycardia, Ectopic Atrial/drug therapy , Animals , Atrial Function/drug effects , Atrial Function/physiology , Bepridil/therapeutic use , Calcium Channel Blockers/therapeutic use , Calcium Channels, L-Type/genetics , Calcium Channels, L-Type/metabolism , Calcium Channels, L-Type/physiology , Disease Models, Animal , Dogs , Down-Regulation/physiology , RNA, Messenger/antagonists & inhibitors , RNA, Messenger/biosynthesis , Tachycardia, Ectopic Atrial/physiopathology , Up-Regulation/drug effects , Up-Regulation/physiology
12.
Europace ; 9(4): 246-51, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17350982

ABSTRACT

AIMS: NIP-141 is a novel multiple ion channel blocker with atrial selective effects. In this study, we examined the effects of NIP-141 on aconitine-induced atrial fibrillation (AF) and rapid atrial pacing-induced atrial effective refractory period (ERP) shortening in dogs. METHODS AND RESULTS: Aconitine AF was induced by the application of aconitine on the right appendage. NIP-141 (10 mg/kg) converted AF to sinus rhythm in 5 of 6 dogs. The Na(+) channel blockers disopyramide (1 mg/kg) and phenytoin (10 mg/kg) also terminated AF, but the I(Kr) blocker (d-sotalol; 4 mg/kg) and a Ca(2+) channel blocker (verapamil; 0.3 mg/kg) did not terminate AF in this model. To clarify the mechanism of AF termination, we examined the effects on ERP and conduction time, but NIP-141 (10 mg/kg) had no significant effects. In a short-term rapid atrial pacing model, NIP-141 (2.5 mg/kg/10 min, followed by 0.033 mg/kg/min) prevented atrial ERP shortening. We also found NIP-141 bound to Na(+) channel site 2 receptor and L-type Ca(2+) channel, but not to Na(+) channel site 1 receptor using radioligands binding assay. CONCLUSION: NIP-141 terminated AF in aconitine-induced AF and prevented the atrial remodelling by short-term rapid pacing in dogs, possibly via the blocking of Na(+) and Ca(2+) channels.


Subject(s)
Atrial Fibrillation/prevention & control , Atrial Fibrillation/physiopathology , Benzopyrans/administration & dosage , Cardiac Pacing, Artificial/methods , Heart Conduction System/drug effects , Heart Conduction System/physiopathology , Refractory Period, Electrophysiological/drug effects , Animals , Atrial Fibrillation/chemically induced , Dogs , Dose-Response Relationship, Drug , Ion Channels/antagonists & inhibitors , Treatment Outcome
13.
J Pharmacol Sci ; 101(4): 303-10, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16891768

ABSTRACT

Mechanisms for the atria-specific action potential-prolonging action of NIP-142 ((3R*,4S*)-4-cyclopropylamino-3,4-dihydro-2,2-dimethyl-6-(4-methoxyphenylacetylamino)-7-nitro-2H-1-benzopyran-3-ol), a benzopyran compound that terminates experimental atrial arrhythmia, was examined. In isolated guinea-pig atrial tissue, NIP-142 reversed the shortening of action potential duration induced by either carbachol or adenosine. These effects were mimicked by tertiapin, but not by E-4031. NIP-142 concentration-dependently blocked the human G protein-coupled inwardly rectifying potassium channel current (GIRK1/4 channel current) expressed in HEK-293 cells with an EC50 value of 0.64 microM. At higher concentrations, NIP-142 blocked the human ether a go-go related gene (HERG) channel current with an EC50 value of 44 microM. In isolated guinea-pig papillary muscles, NIP-142 had no effect on the negative inotropic effect of carbachol under beta-adrenergic stimulation, indicating lack of effect on the muscarinic receptor and Gi protein. These results suggest that NIP-142 directly inhibits the acetylcholine-activated potassium current.


Subject(s)
Anti-Arrhythmia Agents/pharmacology , Atrial Function/drug effects , Benzopyrans/pharmacology , Carbachol/pharmacology , G Protein-Coupled Inwardly-Rectifying Potassium Channels/antagonists & inhibitors , Action Potentials/drug effects , Adenosine/pharmacology , Animals , Atrial Function/physiology , Atropine/pharmacology , Bee Venoms/pharmacology , Carbachol/antagonists & inhibitors , Cell Line , Colforsin/pharmacology , Dose-Response Relationship, Drug , Ether-A-Go-Go Potassium Channels/antagonists & inhibitors , Ether-A-Go-Go Potassium Channels/physiology , G Protein-Coupled Inwardly-Rectifying Potassium Channels/physiology , Guinea Pigs , Humans , In Vitro Techniques , Myocardial Contraction/drug effects , Papillary Muscles/drug effects , Papillary Muscles/physiology , Patch-Clamp Techniques , Potassium Channel Blockers/pharmacology , Time Factors
14.
Pharmacol Res ; 54(2): 136-41, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16725344

ABSTRACT

It is well known that vagal nerve tone plays a crucial role in atrial fibrillation (AF). Acetylcholine-activated potassium current (IKACh) mediates much of the cardiac response to vagal nerve stimulation (VNS), but the contribution of IKACh to AF remains unknown. We investigated the role of the IKACh channel in canine AF models using tertiapin, a selective IKACh blocker. Tertiapin (4-41 nmol kg(-1), i.v.) terminated AF in the canine VNS-induced and aconitine-induced AF models. The muscarinic M-receptor antagonist AF-DX-116 terminated AF in these models, but the adenosine receptor antagonist DPCPX had no effect. Thus it is likely that IKACh activation via the M-receptor has a crucial role in both models. Tertiapin (12 nmol kg(-1), i.v.) preferentially prolonged the atrial effective refractory period (ERP) but not the ventricular ERP under the VNS condition. This peptide (4-41 nmol kg(-1), i.v.) did not affect PQ, QRS and corrected QT intervals in isoflurane-anaesthetised dogs. These results suggest that a selective IKACh blocker is effective in canine AF models without affecting ventricular repolarisation, and might be useful for the treatment of patients with AF.


Subject(s)
Anti-Arrhythmia Agents/pharmacology , Atrial Fibrillation/drug therapy , Bee Venoms/pharmacology , Heart Atria/physiopathology , Potassium Channels/physiology , Refractory Period, Electrophysiological/drug effects , Animals , Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/metabolism , Atrial Fibrillation/physiopathology , Bee Venoms/therapeutic use , Dogs , Dose-Response Relationship, Drug , Electrocardiography , Female , Heart Atria/drug effects , Male
15.
Neurosci Lett ; 340(1): 45-8, 2003 Apr 03.
Article in English | MEDLINE | ID: mdl-12648755

ABSTRACT

3beta-hydroxysteroid dehydrogenase (3beta-HSD) is an enzyme that converts pregnenolone to progesterone. It has been believed that 3beta-HSD is simply a converting enzyme of female steroid hormone. Recently, 3beta-HSD expressing cells were identified in the spinal cord. Steroid synthesis in the nervous system may indicate that steroid plays a role in the nervous system. We report here the increased expression of 3beta-HSD mRNA in the dorsal root ganglion (DRG) after peripheral nerve injury using reverse transcription-polymerase chain reaction and in situ hybridization histochemistry techniques. We detected only a few 3beta-HSD signals in the naïve DRG, and found that 3beta-HSD mRNA expression increased 3 days after injury and this increase was still observed at 14 days. Our results suggest that progesterone may have a role in the process against neuronal injury or in regeneration in the peripheral nervous system.


Subject(s)
Ganglia, Spinal/enzymology , Multienzyme Complexes/biosynthesis , Neurons/enzymology , Progesterone Reductase/biosynthesis , RNA, Messenger/biosynthesis , Sciatic Neuropathy/enzymology , Steroid Isomerases/biosynthesis , Animals , Gene Expression Regulation, Enzymologic/physiology , Rats , Rats, Sprague-Dawley
16.
Pain ; 101(1-2): 65-77, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12507701

ABSTRACT

Neuropathic pain models, such as the chronic constriction injury (CCI) model, are partial nerve injury models where there exist both intact and injured peripheral axons. Recent studies suggested that dorsal root ganglion (DRG) neurons with intact axons also show the alteration of excitability and gene expression and might have some role in the pathophysiological mechanisms of neuropathic pain. The incidence of pain-related behavior after the CCI is unstable and variable. In the present study, we used activating transcription factor 3 (ATF3) expression as a neuronal injury marker, and analyzed a relationship between the number of axotomized neurons and the incidence of pain-related behavior. We divided all rats into three groups according to the percentage of ATF3-immunoreactive (IR) neurons, group 1 (<12.5%), group 2 (12.5-25%), and group 3 (>25%). We found that rats in groups 2 and 3 showed thermal hyperalgesia, whereas only the rats in group 2 developed tactile allodynia from the third day to the fourteenth day after surgery. Rats in group 1 did not show thermal hyperalgesia or tactile allodynia. The DRG neurons in group 2 contained ATF3-IR neurons mainly in medium- and large-sized neurons. In order to investigate brain-derived neurotrophic factor (BDNF) and gamma-aminobutyric acid(A)-receptor (GABA(A)-R) regulation in both intact and injured primary afferent neurons after the CCI, we used a double-labeling method with immunohistochemistry and in situ hybridization, as well as double immunofluorescent staining. The CCI induced an increased number of BDNF-labeled neurons in the ipsilateral DRG and the increase in BDNF expression was observed mainly in small- and medium-sized neurons that were mainly ATF3-negative. On the other hand, the number of GABA(A)-Rgamma2 subunit mRNA-positive neurons decreased in the ipsilateral DRG and GABA(A)-R- and ATF3-labeled neurons rarely overlapped. These changes in molecular phenotype in intact and injured primary afferents may be involved in the pathophysiological mechanisms of neuropathic pain produced by partial nerve injury.


Subject(s)
Ganglia, Spinal/injuries , Neurons, Afferent/physiology , Sciatica/physiopathology , Activating Transcription Factor 3 , Animals , Behavior, Animal , Brain-Derived Neurotrophic Factor/analysis , Brain-Derived Neurotrophic Factor/genetics , Chronic Disease , Ganglia, Spinal/cytology , Gene Expression , Hyperalgesia/epidemiology , Hyperalgesia/physiopathology , Immunohistochemistry , In Situ Hybridization , Incidence , Male , Neurons, Afferent/chemistry , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley , Receptors, GABA-A/analysis , Receptors, GABA-A/genetics , Sciatica/epidemiology , Touch , Transcription Factors/analysis , Transcription Factors/genetics
17.
Pain ; 99(1-2): 121-32, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12237190

ABSTRACT

A variety of molecules released by inflammatory reactions in the dorsal root and dorsal root ganglion (DRG) may play important roles in the pathology of neuronal abnormalities in lumbar disc herniation. In order to elucidate the pathophysiological mechanisms of painful radiculopathy, secondary to lumbar disc herniation, we evaluated pain-related behavior and the change of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) expression in the DRG and dorsal root using a rat model of lumbar disc herniation. In the nucleus pulposus (NP) group, the left L4/5 nerve roots were exposed after hemilaminectomies and autologous intervertebral discs, which were obtained from coccygeal intervertebral discs, were implanted on each of the exposed nerve roots without mechanical compression. Rats in the NP group, but not the sham-operated rats, developed mechanical allodynia on the ipsilateral hind paw for 1 day after surgery and showed a significant increase in the number of NGF-immunoreactive (IR) cells in the nerve root and DRG. NGF-IR cells in the nerve root and DRG included macrophages and Schwann cells, because these cells were labeled for NGF and ED-1 or glial fibrillary acid protein by dual immunostaining. A significant increase in the percentage of BDNF-IR neurons in the DRG was observed in the NP group at 3 days after surgery and the increase in BDNF mRNA expression was confirmed using in situ hybridization histochemistry and reverse transcription-polymerase chain reaction. We also injected NGF into the endoneurial space of the normal rat spinal nerve root and found that the NGF injection produced dose-dependent mechanical allodynia on the ipsilateral hind paw at 1 day after surgery and an increase in the percentage of BDNF-IR neurons in the DRG at 3 days after surgery compared to the group receiving saline injection. These findings suggest that in the lumbar disc herniation model, i.e. neuritis of the nerve root, increased NGF produced by the inflammatory responses in the dorsal root and DRG tissues may affect the production of BDNF in the DRG and may play important roles in the modulation of the dorsal horn neurons. These changes in neurotrophic factors in the primary afferents may be involved in the pathophysiological mechanisms of neuropathic pain produced by lumbar disc herniation.


Subject(s)
Brain-Derived Neurotrophic Factor/genetics , Ganglia, Spinal/physiology , Intervertebral Disc Displacement/complications , Nerve Growth Factor/genetics , Neuralgia/physiopathology , Animals , Behavior, Animal , Brain-Derived Neurotrophic Factor/analysis , Disease Models, Animal , Ganglia, Spinal/cytology , Gene Expression/physiology , Glial Fibrillary Acidic Protein/analysis , Lumbar Vertebrae , Male , Nerve Growth Factor/analysis , Nerve Growth Factor/pharmacology , Neuritis/physiopathology , Neurons, Afferent/chemistry , Neurons, Afferent/physiology , Peripheral Nerves/drug effects , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley
18.
Brain Res Gene Expr Patterns ; 1(2): 107-14, 2002 Jan.
Article in English | MEDLINE | ID: mdl-15018807

ABSTRACT

APC2 (previously known as APCL), a molecule closely related to the adenomatous polyposis coli (APC) tumor suppressor, can deplete cytoplasmic beta-catenin, like APC itself. Recently, it has been shown that APC2 may regulate the localization of p53 and the microtubule stability and/or extension. Although it has been reported that APC2 mRNA is expressed in human brain, the anatomical and ontogenic expression patterns remain unclear. The purpose of this study was to investigate the distribution of mouse Apc2 during mouse development. In the adult brain, Apc2 is expressed predominantly in neurons and throughout the brain. Northern blot analysis demonstrated a high level of Apc2 expression in embryonic and early postnatal brain. Ontogenic analysis has indicated that Apc2 is expressed in neural tissue, including the peripheral nervous system. During development of cortex, retina and cerebellum, Apc2 is expressed in post-mitotic cells. These findings suggest that Apc2 may contribute to the development of neuronal cells.


Subject(s)
Brain/embryology , Brain/metabolism , Cytoskeletal Proteins/biosynthesis , Gene Expression Regulation, Developmental , Animals , Brain/pathology , Cell Differentiation , Cell Movement , In Situ Hybridization , Mice , Mitosis , Neurons/metabolism , RNA, Messenger/metabolism , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...